Patents Assigned to Moleculera Labs, Inc.
  • Diagnostic method for pediatric acute-onset neuropsychiatric syndrome (PANS) and pediatric autoimmune neuropsychiatric disorder associated with streptococci infection (PANDAS)
    Patent number: 10228376
    Abstract: The present invention provides a panel of at least five clinical analyses or tests (using serum samples) to determine the risk of pediatric acute-onset neuropsychiatric syndrome (PANS) and/or pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (PANDAS) in an individual. These include enzyme linked immunosorbent assays (ELISAs) to measure antibody titers against neuronal antigens present in the brain; the neuronal antigens include lysoganglioside, tubulin, dopamine receptor D1, dopamine receptor D2, serotonin receptor 5HT2A, and serotonin receptor 5HT2C. Antibody titers against at least four of these neuronal antigens are required in the present methods; preferably antibody tiers against all of these neuronal antigens are measured. A final assay is used to quantify calcium/calmodulin-dependent protein kinase activity using a neuronal cell line.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: March 12, 2019
    Assignees: Moleculera Labs, Inc., The Board of Regents of the University of Oklahoma, The United States of America, As Represented by the Secretary, Department of Health and Human Serv
    Inventors: Phina Madeleine Cunningham, Craig David Shimasaki, Susan E. Swedo, Christine Kirvan
  • Diagnostic method for pediatric acute-onset neuropsychiatric syndrome (PANS) and pediatric autoimmune neuropsychiatric disorder associated with streptococci infection (PANDAS)
    Patent number: 9804171
    Abstract: The present invention provides a panel of at least five clinical analyses or tests (using serum samples) to determine the risk of pediatric acute-onset neuropsychiatric syndrome (PANS) and/or pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (PANDAS) in an individual. These include enzyme linked immunosorbent assays (ELISAs) to measure antibody titers against neuronal antigens present in the brain; the neuronal antigens include lysoganglioside, tubulin, dopamine receptor D1, dopamine receptor D2, serotonin receptor 5HT2A, and serotonin receptor 5HT2C. Antibody titers against at least four of these neuronal antigens are required in the present methods; preferably antibody tiers against all of these neuronal antigens are measured. A final assay is used to quantify calcium/calmodulin-dependent protein kinase activity using a neuronal cell line.
    Type: Grant
    Filed: February 16, 2016
    Date of Patent: October 31, 2017
    Assignees: The Board of Regents of the University of Oklahoma, Moleculera Labs, Inc., National Institutes of Health
    Inventors: Phina Madeleine Cunningham, Craig David Shimasaki, Susan E. Swedo, Christine Kirvan